Up to 80% of all killer T cells in mouse blood consisted of therapeutic immune cells after researchers combined adoptive cell therapy with a targeted mRNA vaccine.
Glioblastoma remains the most aggressive form of brain cancer. Standard treatments involving surgery, radiation, and chemotherapy frequently fail to prevent tumor recurrence.
Researchers pin high hopes on immunotherapies that activate the body’s immune cells. Yet these treatments hit roadblocks in the brain because too few therapeutic cells reach the tumor and maintain activity.
A research team led by Lukas Bunse, head of the Neuro-Oncology Section at the University Medical Center Mannheim (UMM) and a scientist at the German Cancer Research Center (DKFZ), investigated how to overcome these obstacles.
mRNA vaccination activates dendritic cells to alert therapeutic T cells
The study focuses on T cells genetically engineered in the laboratory to express a specific recognition molecule. This T-cell receptor acts like an antenna to target cancer features.
Simply transferring these therapeutic immune cells to a patient often proves insufficient. The transgenic T cells must multiply, remain active over the long term, and reach the tumor in sufficient numbers.
The mRNA vaccination provides dendritic cells with instructions for producing a characteristic feature of the tumor. These dendritic cells then display a tumor profile on their surface to alert the therapeutic T cells.
Michael Platten, director of the University Clinic for Neurology at UMM and head of department at the DKFZ, co-led the research published in Cancer Research on Nov. 4, 2026.
Combination therapy expands T cells and slows glioblastoma growth in mice
In mice with experimental glioblastomas, the combined treatment caused therapeutic TCR-T cells to proliferate extensively. This expansion altered the properties of the immune cells.
The additional activation enabled more T cells to migrate into the brain tumors. Once inside, the T cells attacked the tumor effectively while displaying fewer signs of functional exhaustion.
Untreated animals and those receiving low-dose monotherapy experienced continued tumor growth. The combination therapy significantly slowed tumor growth and increased the survival time of the animals.
Andreas D. Dobbelstein, first author of the study, noted potential practical benefits for future laboratory production.
“The results provide us with important insights into how cell-based immunotherapies against brain tumors can be improved. In the long term, the combination could, for example, make it possible to use a lower initial dose of therapeutic T cells. This could potentially simplify the labor-intensive process of proliferating T cells in the laboratory,” said Andreas Dobbelstein, first author of the study.
mRNA stimulation enhances human T cells targeting PTPRZ1 protein
The research team tested human immune cells equipped with a receptor that specifically recognizes the PTPRZ1 protein. PTPRZ1 drives tumor growth on human glioblastoma stem cells.
Experiments using human immune cells and mice bearing human glioblastomas showed that additional mRNA stimulation enhanced the tumor-killing ability of the therapeutic T cells. In certain cases, the tumors in the animals regressed completely without causing more severe side effects.
The study was authored by 15 researchers from institutions including the German Cancer Research Center, Heidelberg University, Medizinische Fakultät Mannheim, and BioNTech in Mainz.
Bunse outlined the next developmental steps for the therapy.
“We are already preparing an initial clinical trial for the treatment of glioblastomas with PTPRZ1-targeted TCR-T cells. The combination with mRNA-based stimulation that we have now investigated could serve as a foundation for further clinical developments,” Bunse said.
Researchers plan clinical trials to test safety in patients
Platten emphasized that the evaluation of the combination therapy remains in the preclinical research phase. The researchers plan to test whether the approach translates safely to patients.
“Whether the mRNA booster, in combination with cellular immunotherapy, is also safe and effective in patients must first be investigated in clinical trials,” Platten said.
Keep reading